✦ LIBER ✦

Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors

✍ Scribed by George, Suzanne; Feng, Yang; Manola, Judith; Nucci, Marisa R.; Butrynski, James E.; Morgan, Jeffrey A.; Ramaiya, Nikhil; Quek, Richard; Penson, Richard T.; Wagner, Andrew J.; Harmon, David; Demetri, George D.; Krasner, Carolyn

Book ID: 126317828
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 132 KB
Volume: 120
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.28476

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunohistochemical expression of estrog

Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma

✍ Mario M. Leitao Jr.; Martee L. Hensley; Richard R. Barakat; Carol Aghajanian; Gi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 316 KB

CA125 response and disease stabilisation

CA125 response and disease stabilisation are associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer

✍ Smyth, J.F.; Bowman, A.; Gabra, H.; Lessels, A.; Stewart, M.; Young, A.; Langdon 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 356 KB

1046 POSTER Expression of NF-kB Transcri

1046 POSTER Expression of NF-kB Transcription Factor, C-erbB2, Estrogen and Progesterone Receptors in Tumours of Patients With Breast Cancer

✍ D. Shapochka; S. Zaletok 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 40 KB

A phase II study single agent of afliber

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

✍ H.J. Mackay; R.J. Buckanovich; H. Hirte; R. Correa; P. Hoskins; J. Biagi; L.P. M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 309 KB

Germ-line mutations in BRCA1 or BRCA2 in

Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A

✍ Patricia A. Mote; Jennifer A. Leary; Kelly A. Avery; Kerstin Sandelin; Georgia C 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

## Abstract The breast cancer susceptibility genes __BRCA1__ and __BRCA2__ are responsible for a large proportion of familial breast and ovarian cancer, yet little is known of how disruptions in the functions of the proteins these genes encode increased cancer risk preferentially in hormone‐depende

A randomized phase III trial of adjuvant

A randomized phase III trial of adjuvant endocrine therapy with tamoxifen for one year (TAM1) vs tamoxifen for two years (TAM2) in postmenopausal high risk patients with estrogen receptor positive or estrogen receptor unknown breast cancer. A DBCG study

✍ J. Andersen; M. Andersson; K.W. Andersen; P. Dombemowsky; H.T. Mouridsen; C. Ros 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 300 KB